The mission of the to-be-established NIDA National Drug Abuse Clinical Trials Network (CTN) is to improve the quality of drug abuse treatment nationally by (1) accelerating the pace of treatment research, testing findings from small controlled studies in real-life treatment settings, and (2) accelerating community-treatment-program implementation of new treatment technologies via dissemination and training. Specific CTN objectives include conducting studies in the areas of pharmacological, behavioral and practice research in a range of treatment settings and clinical populations; conducting studies on how best to translate science-based findings into clinical practice; encouraging collaboration between community treatment facilities and academic researchers; and assessing the health and systems impact of the implementation of new treatment modalities. The New York City East Side (NYC-ES) Node will contribute the following to this overall mission: (1) leadership in addiction research, training and treatment, (2) broad clinical trials expertise and extensive clinical capacity, (3) a state-of the-art clinical trials data management system and expertise, (4) leadership in dissemination and evaluation of addiction treatment training material, and (5) unique capacity to contribute to the network in the following areas (a) health services and health outcomes research, (b) genetics and pharmacogenetics related to vulnerability to drug addiction, (c) central data management. The NYC-ES Node is a consortium of academic and clinical investigators/providers who have a longstanding track record of fruitful collaboration in research, training, and clinical service delivery for the addictive disorders. The Community-based Treatment Programs (CTPs) are characterized by programmatic and treatment-model diversity, and provide access to an overall clinical population of more than 10,000 patients with extensive diagnostic, ethnic and gender diversity. Regional Research and Training Center (RRTC) components include (1) the Rockefeller University Laboratory for the Study of Addictive Disease and its Cornell-affiliated programs, (2) the NYU School of Medicine Division of Alcoholism and Drug Abuse; (3) a group of NYU and Nathan Kline Institute investigators with extensive large scale clinical trials experience; and (4) the Epidemiology and Health Services Research Laboratory at the Nathan Kline Institute.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZDA1)
Program Officer
Levy, Janet
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
New York University
Schools of Medicine
New York
United States
Zip Code
McCollister, Kathryn E; Leff, Jared A; Yang, Xuan et al. (2018) Cost of pharmacotherapy for opioid use disorders following inpatient detoxification. Am J Manag Care 24:526-531
Levran, Orna; Correa da Rosa, Joel; Randesi, Matthew et al. (2018) A non-coding CRHR2 SNP rs255105, a cis-eQTL for a downstream lincRNA AC005154.6, is associated with heroin addiction. PLoS One 13:e0199951
Crist, R C; Doyle, G A; Nelson, E C et al. (2018) A polymorphism in the OPRM1 3'-untranslated region is associated with methadone efficacy in treating opioid dependence. Pharmacogenomics J 18:173-179
Crist, Richard C; Li, James; Doyle, Glenn A et al. (2018) Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate. Am J Drug Alcohol Abuse 44:431-440
Lee, Joshua D; Nunes, Edward V; Mpa, Patricia Novo et al. (2016) NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale. Contemp Clin Trials 50:253-64
Nunes, Edward V; Lee, Joshua D; Sisti, Dominic et al. (2016) Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence. Contemp Clin Trials 51:34-43
Ling, Walter; Hillhouse, Maureen P; Saxon, Andrew J et al. (2016) Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study. Addiction 111:1416-27
Clarke, T-K; Crist, R C; Ang, A et al. (2014) Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females. Pharmacogenomics J 14:303-8
Bogenschutz, Michael P; Donovan, Dennis M; Mandler, Raul N et al. (2014) Brief intervention for patients with problematic drug use presenting in emergency departments: a randomized clinical trial. JAMA Intern Med 174:1736-45
Morgan-Lopez, Antonio A; Saavedra, Lissette M; Hien, Denise A et al. (2013) Synergy between seeking safety and twelve-step affiliation on substance use outcomes for women. J Subst Abuse Treat 45:179-89

Showing the most recent 10 out of 55 publications